ArmaGen Receives Rare Pediatric Disease Designation from FDA for MPS I

ArmaGen Inc. announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation to AGT-181, a potential treatment for patients with Hurler syndrome (MPS I). The designation of rare pediatric disease status will make ArmaGen eligible to request a Rare Pediatric Disease Priority Review Voucher (“Rare Pediatric DPRV”) upon approval of AGT-181 by the FDA.

Read the full press release.

This entry was posted in News, Uncategorized. Bookmark the permalink.

Comments are closed.